SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Kos Pharmaceuticals, Inc (KOSP)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: mopgcw10/31/2004 7:38:44 PM
  Read Replies (1) of 118
 
GS: Kos Pharmaceuticals, Inc. EPS (FY Dec) 2004E $1.67, 2005E $2.32 In-Line/Neutral
(KOSP) $34.69

We have reduced our Advicor and Azmacort revenue estimate for third quarter 2004,
resulting in a decrease of $0.02 to our 3Q'04 EPS estimate. Our revenue changes
were driven by lower than expected total prescriptions for Advicor and Azmacort in
this quarter. We have lowered our revenue estimate for Advicor to $27.2 million
from $29.8 million and for Azmacort to $13.6 million from $16.1 million. FY2004
EPS has been decreased to $1.67 from $1.69. We maintain our In-Line rating and our
Neutral coverage view. Kos will release 3Q'04 EPS on November 3, 2004 before the
market opens. A conference call is scheduled that day at 11:00 AM EST
(1-913-981-9401).
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News